Proliferative vitreoretinopathy

Proliferative vitreoretinopathy (PVR) is a disease that develops as a complication of rhegmatogenous retinal detachment. PVR occurs in about 8–10% of patients undergoing primary retinal detachment surgery and prevents the successful surgical repair of rhegmatogenous retinal detachment. PVR can be treated with surgery to reattach the detached retina but the visual outcome of the surgery is very poor.[1][2] A number of studies have explored various possible adjunctive agents for the prevention and treatment of PVR, such as methotrexate, although none have yet been licensed for clinical use.[3]

Proliferative vitreoretinopathy
SpecialtyOphthalmology 

PVR was originally referred to as massive vitreous retraction and then as massive periretinal proliferation. The name Proliferative vitreo retinopathy was provided in 1989 by the Silicone Oil Study group. The name is derived from proliferation (by the retinal pigment epithelial and glial cells) and vitreo retinopathy to include the tissues which are affected, namely the vitreous humor (or simply vitreous) and the retina.[4]

Predisposing factors

Predisposing factors for Postoperative PVR are preoperative PVR, aphakia, high levels of vitreous proteins,[5] duration of retinal detachment before corrective surgery, the size of the retinal hole or tear, intra-ocular inflammation, vitreous hemorrhage, and trauma to the eye. An equation to calculate the patient's risk for acquiring PVR is:

PVR score = 2.88 × (Grade C PVR)+ 1.85 × (Grade B PVR) + 2.92 × (aphakia) + 1.77 × (anterior uveitis) + 1.23 × (quadrants of detachment) + 0.83 × (vitreous haemorrhage) + 23 × (previous cryotherapy)

1 is added if the risk factor is present and 0 if the risk factor is absent. A patient is at a high risk for developing PVR if their PVR score is >6.33.[6]

Pathology

During rhegmatogenous retinal detachment, fluid from the vitreous humor enters a retinal hole. The mechanisms by which retinal holes or tears form are not fully understood yet. The accumulation of fluid in the subretinal space and the tractional force of the vitreous on the retina result in rhegmatogenous retinal detachment. During this process the retinal cell layers come in contact with vitreous cytokines. These cytokines trigger the ability of the retinal pigmented epithelium (RPE) to proliferate and migrate. The process involved resembles fibrotic wound healing by the RPE cells. The RPE cells undergo epithelial-mesenchymal transition (EMT) and develop the ability to migrate out into the vitreous. During this process the RPE cell layer-neural retinal adhesion and RPE-ECM (extracellular matrix) adhesions are lost. The RPE cells lay down fibrotic membranes while they migrate and these membranes contract and pull at the retina. All these finally lead to secondary retinal detachment after primary retinal detachment surgery. A number of studies have also shown that arachidonic acid metabolic cascade (one of the major inflammatory cascades) is important in the development of PVR. COX-2 expression was found in human idiopathic epiretinal membranes.[7] Phospholipase A2 and cyclooxygenase blocking reduced structural abnormalities of the rat retina in concanavalin model of PVR[8] and reduced the frequency of membrane formation by 43% in the dispase model of PVR and by 31% in the concanavalin one. Lornoxicam not only normalized the expression of cyclooxygenases in both models of PVR, but also neutralized the changes of the retina and the choroid thickness caused by the injection of pro-inflammatory agents.[9]

PVR is graded as Grade A, B, or C by the Silicone Oil Study and as Grade A, B, C, or D by the Retina Society Terminology Committee.[10]

  • Grade A is characterized by the appearance of vitreous haze and RPE cells in the vitreous.
  • Grade B is characterized by wrinkling of the edges of the retinal tear or the inner retinal surface.
  • Grade C is characterized by the presence of retinal membranes.

Retinal membranes

The RPE cells migrate out into the vitreous, proliferate excessively and lay down ECM on both side sides of the detached retina. The ECM laid on the vitreous side of the retina are referred to as epiretinal or preretinal membranes (ERM) and those laid down between the RPE layer and the photoreceptors are referred to as subretinal or retroretinal membranes (SRM) . The two membranes differ in composition in that the ERM is composed of RPE cells, glial cells, macrophages and fibrocytes, while the SRM is rich in RPE cells. The subretinal membranes are of two types. One forms as diffuse sheets, which are not contractile and either lack or contain very little ECM. The presence of this type of membrane does not usually affect retinal reattachment surgery. The retina can be reattached even with the membrane in place. The other type forms as very thick contractile membranes which pull at the retina. These are opaque and block the light falling on the retina so the retinal reattachment surgery needs to be performed after manually peeling the membrane off.[11][12]

Cytokines involved in PVR

A number of cytokines such as tumor necrosis factor alpha (TNFα), transforming growth factor beta 2 (TGFβ2), platelet derived growth factor (PDGF) and interleukins have been shown to play a role in PVR progression.

TGFβ2 levels have been shown to be elevated up to three times normal during the progression of PVR. TGFβ2 is the most predominant isoform in the eye and is secreted as a latent inactive peptide into the vitreous by epithelial cells of the ciliary body and the lens epithelium and is also produced by the RPE cells and the Muller cells of the retina. TGFβ2 is known to induce EMT in RPE cells and fibrosis in the eye.[13] Expression of PDGF in particular PDGF-AA is triggered during ocular injury and contributes to PVR pathology.[14] RPE cells express the receptor for hepatocyte growth factor (HGF). HGF stimulates RPE cell migration and its presence is also strongly detected in retinal membranes. Interleukin 6 levels are elevated in the vitreous humor during PVR.[15]

References
  1. Leaver PK (1995). "Proliferative vitreoretinopathy". British Journal of Ophthalmology. 79 (10): 871–872. doi:10.1136/bjo.79.10.871. PMC 505283. PMID 7488570.
  2. "Proliferative Vitreoretinopathy". Retina and Vitreous of Texas. Archived from the original on 2004-05-06. Retrieved 2009-05-28.
  3. Balas, Michael; Abdelaal, Ahmed; Popovic, Marko M.; Kertes, Peter J.; Muni, Rajeev H. (2022-10-01). "Intravitreal Methotrexate for the Prevention and Treatment of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment: A Systematic Review". Ophthalmic Surgery, Lasers and Imaging Retina. 53 (10): 561–568. doi:10.3928/23258160-20220920-04. ISSN 2325-8160.
  4. Ceron OM, Arroyo JG (2009). "Better Outcomes May Be Ahead for PVR". Review of Ophthalmology. 16: 1. Retrieved 2009-05-29.
  5. Kon CH, Asaria RH, Occleston NL, Khaw PT, Aylward GW (2000). "Risk factors for proliferative vitreoretinopathy after primary vitrectomy: a prospective study". British Journal of Ophthalmology. 84 (5): 506–511. doi:10.1136/bjo.84.5.506. PMC 1723478. PMID 10781515.
  6. Kon CH, Tranos P, Aylward GW (2005). "Risk Factors in Proliferative Vitreoretinopathy". In Kirchoff B, Wong D (eds.). Vitreo-retinal Surgery. Springer Berlin Heidelberg. pp. 121–134. ISBN 978-3-540-20044-4.
  7. Kase S; Saito W; Ohno S; Ishida S. (May 2010). "Cyclo-oxygenase-2 expression in human idiopathic epiretinal membrane". Retina. 30 (5): 719–23. doi:10.1097/IAE.0b013e3181c59698. PMID 19996819. S2CID 205650971.
  8. Erdiakov A, Gavrilova S (August 2014). "Influence of lornoxicam and triamcinolone on the dynamics of eye remodeling in concanavalin model of inflammation". Acta Ophthalmologica. 92. doi:10.1111/j.1755-3768.2014.F077.x. S2CID 71595604.
  9. Tikhonovich, Marina V.; Erdiakov, Aleksei K.; Gavrilova, Svetlana A. (2017-06-21). "Nonsteroid anti-inflammatory therapy suppresses the development of proliferative vitreoretinopathy more effectively than a steroid one". International Ophthalmology. 38 (4): 1365–1378. doi:10.1007/s10792-017-0594-3. ISSN 0165-5701. PMID 28639085. S2CID 4017540.
  10. Spirn MJ, Regillo C (January 2008). "Proliferative Vitreoretinopathy". Retinal Physician. Retrieved 2009-05-29.
  11. Hiscott P, Grierson I (1991). "Subretinal membranes of proliferative vitreoretinopathy". British Journal of Ophthalmology. 75 (1): 53. doi:10.1136/bjo.75.1.53. PMC 504108. PMID 1991089.
  12. Casaroli-Marano RP, Pagan R, Vilaró S (1999). "Epithelial–Mesenchymal Transition in Proliferative Vitreoretinopathy: Intermediate Filament Protein Expression in Retinal Pigment Epithelial Cells". Investigative Ophthalmology & Visual Science. 40 (9): 2062–2072. PMID 10440262.
  13. Connor TB, Roberts AB, Spom MB, Danielpour D, Dart LL, Michels RG, Bustros SD, Enger C, Kato H, Lansing M, Hayashi H, Glaser BM (1989). "Correlation of Fibrosis and Transforming Growth Factor-β Type 2 Levels in the Eye". The Journal of Clinical Investigation. 83 (5): 1661–1666. doi:10.1172/JCI114065. PMC 303874. PMID 2708527.
  14. Andrews A, Balciunaite E, Leong FL, Tallquist M, Soriano P, Refojo M, Kazlauskas A (1999). "Platelet-derived growth factor plays a key role in proliferative vitreoretinopathy". Investigative Ophthalmology & Visual Science. 40 (11): 2683–2689. PMID 10509666.
  15. Kauffmann DJ, van Meurs JC, Mertens DA, Peperkamp E, Master XC, Gerritsen ME (1994). "Cytokines in Vitreous Humor: Interleukin-6 Is Elevated in Proliferative Vitreoretinopathy". Investigative Ophthalmology & Visual Science. 35 (3): 900–906. PMID 8125753.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.